Today: 19 May 2026
Cadence stock ends slightly higher as year-end trading turns to Fed minutes
29 December 2025
1 min read

Cadence stock ends slightly higher as year-end trading turns to Fed minutes

NEW YORK, December 29, 2025, 01:10 ET — Market closed

  • Cadence shares last closed at $318.89, up 0.4%.
  • Traders head into the final 2025 sessions watching Fed minutes and rate-cut expectations.
  • Investors are tracking whether market leadership broadens beyond mega-cap tech.

Cadence Design Systems (CDNS.O) shares last closed up 0.4% at $318.89, as U.S. markets remained shut early Monday ahead of the final trading days of 2025.

The chip-design software maker is often treated as a proxy for investment in advanced semiconductors, with investors using it to express views on demand for tools that help companies design and test chips.

That matters now because thin year-end volumes can amplify moves, while investors are recalibrating expectations for U.S. interest rates going into 2026.

In its latest session, Cadence traded between $317.00 and $319.30 and ended with about 551,000 shares changing hands.

Broader equity sentiment has been underpinned by hopes the Federal Reserve will keep cutting rates after lowering its benchmark by 75 basis points over its last three meetings of 2025 to 3.50%-3.75%, Reuters reported.

With major U.S. indexes near record highs, investors have focused on whether leadership rotates beyond technology after a late-year rebound in the sector.

“Momentum is certainly on the side of the bulls,” said Paul Nolte, a senior wealth adviser and market strategist at Murphy & Sylvest Wealth Management, referring to the broader market setup into year-end. Reuters

Cadence’s core business is electronic design automation, or EDA — software used to design, verify and simulate chips before they are manufactured, a step that has grown more complex as AI and advanced computing drive larger designs.

In late October, the company reported quarterly results that highlighted a record backlog of $7.0 billion and said it was raising its 2025 revenue outlook to about 14% year-on-year growth.

Cadence has also flagged that U.S.-China trade tensions can influence demand in China, a key semiconductor market, in earlier guidance and commentary.

Peers include Synopsys (SNPS.O) and Siemens’ EDA business, which compete in chip design and verification software as chipmakers invest in AI-linked systems.

Before the next session, investors will watch for minutes from the Fed’s Dec. 9-10 meeting, due Tuesday, for clues on how policymakers debated the path of rate cuts.

Markets are also alert to any signal around President Donald Trump’s choice for the next Fed chair, which Reuters said could sway trading in the coming week.

On the corporate calendar, Cadence is expected to report earnings around Feb. 17, according to Nasdaq’s earnings schedule, putting guidance and backlog trends back in focus early in 2026.

Sources: Reuters market reporting and Cadence/market data pages.

Stock Market Today

  • Deutsche Bank Sees No Immediate Threat to Risk Assets Amid Energy Concerns
    May 19, 2026, 10:05 AM EDT. Deutsche Bank analysts stated that the current environment lacks the conditions that triggered aggressive selloffs in riskier assets during past energy shocks. They suggest investors need not worry about immediate pressure on risk assets, which include stocks and high-yield bonds, despite recent market volatility linked to energy sector developments.

Latest articles

Bakkt Up Early After Director Buys $4.85M in Shares

Bakkt Up Early After Director Buys $4.85M in Shares

19 May 2026
Bakkt shares jumped 14.2% to $9.96 in pre-market trading Tuesday after a filing showed director Michael Alfred’s vehicle bought $4.85 million in stock. SEC documents said Alfred acquired 585,000 shares last week via Alpine Fox LP. CEO Akshay Naheta exercised options for 33,557 shares at $10 each. Bakkt recently reported Q1 revenue of $243.6 million, down sharply from a year earlier.
Relay Therapeutics Shares Rise In Pre-Market Ahead Of Key Drug Update

Relay Therapeutics Shares Rise In Pre-Market Ahead Of Key Drug Update

19 May 2026
Relay Therapeutics shares jumped 11.3% to $13.47 in premarket trading Tuesday after reporting a 60% volumetric response rate in 20 evaluable patients from its Phase 2 trial of zovegalisib for vascular anomalies. The company said 95% of patients saw some lesion reduction at 12 weeks. No patients discontinued due to adverse events. The regular Nasdaq session was set to open at 9:30 a.m. ET.

Popular

Evolution stock jumps on €2 billion move

Evolution stock jumps on €2 billion move

19 May 2026
Evolution AB shares surged 9% in Stockholm after the company announced a €2 billion share buyback, one of Sweden’s largest. The buyback starts immediately and may run until the 2027 annual meeting, capped at 10% of shares. The OMXS30 index rose just 0.75% in comparison. Evolution also secured a €300 million revolving credit facility from J.P. Morgan SE and Citibank Europe.
HFCL jumps 10% on heavy volumes even as MarketsMojo keeps “Strong Sell” callNEW YORK, December 29, 2025, 00:11 ET
Previous Story

HFCL jumps 10% on heavy volumes even as MarketsMojo keeps “Strong Sell” callNEW YORK, December 29, 2025, 00:11 ET

Hims & Hers stock slides into year-end as investors weigh Ohio buildout and macro calendar
Next Story

Hims & Hers stock slides into year-end as investors weigh Ohio buildout and macro calendar

Go toTop